Traws Pharma, Inc.(ONTX)Stock Analysis
AI analysis on 6,000+ stocks →Deep AI analysis on 6,000+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $46.2M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ONTX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Traws Pharma, Inc. (ONTX), a Healthcare sector company. ONTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $46.2m in revenue. Based on the latest XBRL financial filings, Traws Pharma, Inc. reports trailing revenue of $2.7M, net income of $17.6M, free cash flow of $7.6M. Top institutional holders of ONTX by reported 13-F value include ORBIMED ADVISORS, ORBIMED ADVISORS, PERCEPTIVE ADVISORS, based on the most recent SEC filings. ONTX trades on the Nasdaq exchange and files with the SEC under CIK 1130598. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ONTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Traws Pharma, Inc. directly from SEC EDGAR.
Revenue
Q4 2024
$2.7M
Net Income
Q4 2024
$17.6M
Free Cash Flow
Q4 2024
$7.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+1134.5% YoYNet Income
+148.4% YoYOperating Income
+11.9% YoYEPS (Diluted)
+191.1% YoYTotal Assets
-53.2% YoYOp. Cash Flow
-1.4% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $2.8M +1134.5% | $226.0K +0.0% | $226.0K +0.0% | $226.0K -2.2% | $231.0K -89.4% | $2.2M |
| Net Income | $9.2M +148.4% | $-18.9M +0.1% | $-19.0M -17.3% | $-16.2M +35.8% | $-25.2M -17.0% | $-21.5M |
| Operating Income | $-17.9M +11.9% | $-20.3M -3.4% | $-19.6M -19.0% | $-16.5M +34.0% | $-25.0M -15.2% | $-21.7M |
| EPS (Diluted) | $0.82 +191.1% | $-0.90 +1.1% | $-0.91 +5.2% | $-0.96 | — | — |
| Total Assets | $10.6M -53.2% | $22.7M -42.4% | $39.4M -29.0% | $55.5M +177.6% | $20.0M -15.6% | $23.7M |
| Operating Cash Flow | $-18.2M -1.4% | $-17.9M -10.1% | $-16.3M +16.4% | $-19.5M +15.5% | $-23.1M -10.8% | $-20.8M |
Track ONTX with AI-powered research
10 AI analysts debate this stock daily. Free to start.
Available Research
13F Pro tracks comprehensive data for Traws Pharma, Inc. including:
Top Institutional Holders of ONTX
ORBIMED ADVISORS LLC
$5.4M605,531 shORBIMED ADVISORS LLC
$3.6M605,531 shPERCEPTIVE ADVISORS LLC
$1.5M164,157 shORBIMED ADVISORS LLC
$1.4M605,531 shADAGE CAPITAL PARTNERS GP, L.L.C.
$1.3M730,000 shIkarian Capital, LLC
$1.2M678,142 shORBIMED ADVISORS LLC
$1.1M605,531 shORBIMED ADVISORS LLC
$1.1M605,531 shAlyeska Investment Group, L.P.
$1.0M116,714 shPERCEPTIVE ADVISORS LLC
$970.1K421,781 sh
| Fund | Value | Shares |
|---|---|---|
| ORBIMED ADVISORS LLC | $5.4M | 605,531 |
| ORBIMED ADVISORS LLC | $3.6M | 605,531 |
| PERCEPTIVE ADVISORS LLC | $1.5M | 164,157 |
| ORBIMED ADVISORS LLC | $1.4M | 605,531 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $1.3M | 730,000 |
| Ikarian Capital, LLC | $1.2M | 678,142 |
| ORBIMED ADVISORS LLC | $1.1M | 605,531 |
| ORBIMED ADVISORS LLC | $1.1M | 605,531 |
| Alyeska Investment Group, L.P. | $1.0M | 116,714 |
| PERCEPTIVE ADVISORS LLC | $970.1K | 421,781 |
More Healthcare Companies
View all Healthcare →Unlock Full Research for ONTX
Get detailed financial analysis, insider activity, institutional flows, AI-powered debates, and quality rankings for Traws Pharma, Inc. and 6,000+ other companies.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ONTX a good stock to buy?
13F Pro's AI-powered analysis of Traws Pharma, Inc. (ONTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ONTX are available on the ONTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ONTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ONTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Traws Pharma, Inc.'s investment landscape.